English

Klaria postpones interim Q1 report

Report this content

Klaria Pharma Holding AB (publ) has decided to postpone the publication of the interim report for the first quarter of 2026. Work has taken longer than expected and the interim report will be published on Friday, May 29. The previously announced date was May 21st.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
info@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.

Subscribe